




WORLD HEALTH ORGANIZATION  
ORGANISATION MONDIALE DE LA SANTE

37363  
WHO/TRM/91.3

DISTR.: GENERAL(E)  
ORIGINAL: ENGLISH

REPORT OF  
THE CONSULTATION TO REVIEW THE DRAFT GUIDELINES FOR THE  
ASSESSMENT OF HERBAL MEDICINES

Munich, Germany, 19-21 June 1991



This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced or translated, in part or in whole, but not for sale or use in conjunction with commercial purposes.

The views expressed in documents by named authors are solely the responsibility of those authors.

Ce document n'est pas une publication officielle de l'Organisation mondiale de la Santé (OMS) et tous les droits y afférents sont réservés par l'Organisation. S'il peut être commenté, résumé ou cité sans aucune restriction, il ne saurait cependant être reproduit ni traduit, partiellement ou en totalité, pour la vente ou à des fins commerciales.

Les opinions exprimées dans les documents par des auteurs cités nommément n'engagent que lesdits auteurs.

## TABLE OF CONTENTS

	<u>Page</u>
1. Introduction .....	2
2. Opening Session .....	3
3. Safety and Quality Control Issues Associated with Over-the-Counter Herbal Medicines .....	3
4. Overview of Current Activities by Countries .....	3
5. The Pharmaceutical Assessment of Herbal Remedies .....	4
6. The Safety and Efficacy of Herbal Medicines .....	4
7. Further Action .....	4
8. Guidelines .....	4
9. Closure of the Meeting .....	9
 ANNEX I List of Participants .....	 10
ANNEX II Welcome Address - O. Akerele, WHO, Geneva, Switzerland .....	13
ANNEX III Address by A. Reithmeier, Bavarian Ministry of the Interior, Germany .....	15
ANNEX IV Summary of the Presentation on the Safety and Quality Control Issues Associated with Over-the-Counter Herbal Medicines .....	17
ANNEX V Extracts from Papers Presented by Country Representatives and Others on the Regulation, Development and Control of Herbal Medicines .....	19
ANNEX VI Closing Remarks - O. Akerele, WHO, Geneva, Switzerland .....	28

## 1. INTRODUCTION

The Fourth International Conference of Drug Regulatory Authorities, held in Tokyo in 1986, organized a workshop on the regulation of herbal medicines moving in international commerce. Another workshop on the same subject was held as part of the Fifth International Conference of Drug Regulatory Authorities, held in Paris in 1989. Both workshops confined their considerations to the commercial exploitation of traditional medicines through over-the-counter labelled products. It was concluded that the World Health Organization should consider preparing model guidelines containing basic elements of legislation designed to assist those countries wishing to develop appropriate legislation and registration. The draft document now presented, represents the Organization's response to this request.

Earlier drafts of the guidelines were sent to Information Officers in countries. These are senior government officials designated by their ministries to assist WHO in its task of promoting the exchange of information on drugs. Their constructive suggestions were submitted to the Consultation for consideration.

### 1.1 Objective

The objective of the guidelines is basically to define the criteria for the evaluation of safety, efficacy, and quality of herbal medicines, and thereby to assist national regulatory authorities, scientific organizations, and manufacturers to undertake an assessment of the documentation/submission/dossiers in respect of such products.

### 1.2 The Guidelines

The document deals first with pharmaceutical assessment and covers such issues as those related to the identification of plant material, galenic forms, analytics and stability.

Safety assessment is, no doubt, the most singular concern for the registration of any manufactured herbal remedy and should minimally cover documentation of safety based on experience of usage and toxicological studies, where indicated. For example, where chronic toxicological events have not been noticed by practitioners or patients.

Assessment of efficacy and intended use covers all important aspects of efficacy assessment, including evaluation of traditional usage through evaluation of the literature, and evidence required to support indications.

Combination products and additives are issues that are important to regulatory authorities, especially the addition of pharmacologically-active compounds such as steroids into herbal preparations.

Product information and promotion protect the consumers and manufacturers and should therefore be focussed on as a condition for registration.

Lastly, the Organization believes that a refined version of the guidelines should be useful to drug regulatory authorities and industry alike and could be adapted as required for the assessment of other traditional medicines derived from different sources.

### 1.3 The outcome

The results of this Consultation should not and could not represent the final word on the subject. WHO will circulate the finalized guidelines widely to countries for adoption to particular national situations and in their present form they should not be considered as an authoritative statement with legal force.

Since the request for WHO to prepare guidelines for the assessment of herbal medicines came from the 5th International Conference of Drug Regulatory Authorities in Paris in 1989, it follows that the report of this Consultation including the finalized guidelines will be presented to the 6th International Conference on Drug Regulatory Authorities in Ottawa in October 1991.

## 2. OPENING SESSION

The meeting was opened by Dr O. Akerele, who welcomed the participants on behalf of the Director-General of the World Health Organization (see Annex II).

Mr J. Burges, Chairman, World Federation of Proprietary Medicine Manufacturers, also welcomed participants and introduced the Bavarian Government authority inviting him to address the meeting.

On behalf of the Bavarian Government, Alfonse Reithmeier of the Bavarian Ministry of the Interior also welcomed the participants to Munich. He observed that the Interior Ministry is the supreme health authority in Bavaria and is in charge of all pharmaceutical affairs (see Annex III).

Dr F.H Kemper, Germany was elected Chairperson and Mrs M. Garman Kasperek, Rapporteur.

## 3. SAFETY AND QUALITY CONTROL ISSUES ASSOCIATED WITH OVER-THE-COUNTER HERBAL MEDICINES

Based on a selection from representative scientific literature, Dr Norman Farnsworth introduced his background paper (Annex IV) noted that over-the-counter herbal medicines do not usually present a major problem with regard to toxicity. However, this does not minimize the need to have quality assurance procedures in place for products being offered to the public, that are intended to have a palliative or curative effect on selected disease states.

In Annex IV examples are cited of some potential problems in this area of safety and quality control of over-the-counter herbal medicines. The Consultation concurred that it should not be difficult to develop guidelines that could be applied to the quality control of these herbal medicines that would adequately minimize the potential problems cited in the Annex. However, it was agreed that a greater problem was the acceptance and implementation of such guidelines on a national or global basis.

## 4. OVERVIEW OF CURRENT ACTIVITIES BY COUNTRIES

Presentations on the regulation, development and control of herbal medicines were made by participants of 11 countries, two from the Americas, four from Asia and five from Europe and also by a participant from the WHO Regional Office for the Eastern Mediterranean. Extracts from these presentations may be found in Annex V.

## 5. THE PHARMACEUTICAL ASSESSMENT OF HERBAL REMEDIES

A Working Group of the participants considered in detail the pharmaceutical assessment of herbal medicines including questions on purity and contamination.

## 6. THE SAFETY AND EFFICACY OF HERBAL MEDICINES

A further Working Group of the participants studied the assessment of the safety and efficacy of herbal medicines, and the necessary information for the consumer on these products. Combination products were given special attention since herbal medicines often contain more than one ingredient. Prophylactic use of these medicines was also briefly discussed.

## 7. FURTHER ACTION

The participants of the Consultation having reviewed the draft guidelines for the assessment of herbal medicines and amended them, recommended that the amended guidelines as printed below, should be widely distributed to Member States by WHO and submitted for consideration to the Sixth International Conference of Drug Regulatory Authorities to be held in Ottawa in October 1991.

## 8. GUIDELINES FOR THE ASSESSMENT OF HERBAL MEDICINES

### 8.1. Introduction

For the purpose of these guidelines "HERBAL MEDICINES" should be regarded as:

Finished, labelled medicinal products that contain as active ingredients aerial or underground parts of plants, or other plant material, or combinations thereof, whether in the crude state or as plant preparations. Plant material includes juices, gums, fatty oils, essential oils, and any other substances of this nature. Herbal medicines may contain excipients in addition to the active ingredients. Medicines containing plant material combined with chemically defined active substances, including chemically defined, isolated constituents of plants, are not considered to be herbal medicines.

Exceptionally, in some countries herbal medicines may also contain, by tradition, natural organic or inorganic active ingredients which are not of plant origin.

The past decade has seen a significant increase in the use of herbal medicines. As a result of WHO's promotion of traditional medicine, countries have been seeking the assistance of WHO in identifying safe and effective herbal medicines for use in national health care systems. In 1989, one of the many resolutions adopted by the World Health Assembly in support of national traditional medicine programmes drew attention to herbal medicines as being of great importance to the health of individuals and communities (WHA 42.43). There was also an earlier resolution (WHA 22.54) on pharmaceutical production in developing countries; this called on the Director-General to provide assistance to the health authorities of Member States to ensure that the drugs used are those most appropriate to local circumstances, that they are rationally used, and that the requirements for their use are assessed as accurately as possible. Moreover, the Declaration of Alma-Ata in 1978 provided for inter alia, the accommodation of proven traditional remedies in national

drug policies and regulatory measures. In developed countries, the resurgence of interest in herbal medicines has been due to the preference of many consumers for products of natural origin. In addition, manufactured herbal medicines from their countries of origin often follow in the wake of migrants from countries where traditional medicines play an important role.

In both developed and developing countries, consumers and health care providers need to be supplied with up-to-date and authoritative information on the beneficial properties, and possible harmful effects, of all herbal medicines.

The Fourth International Conference of Drug Regulatory Authorities, held in Tokyo in 1986, organized a workshop on the regulation of herbal medicines moving in international commerce. Another workshop on the same subject was held as part of the Fifth International Conference of Drug Regulatory Authorities, held in Paris in 1989. Both workshops confined their considerations to the commercial exploitation of traditional medicines through over-the-counter labelled products. The Paris meeting concluded that the World Health Organization should consider preparing model guidelines containing basic elements of legislation designed to assist those countries who might wish to develop appropriate legislation and registration.

The objective of these guidelines, therefore, is to define basic criteria for the evaluation of quality, safety, and efficacy of herbal medicines and thereby to assist national regulatory authorities, scientific organizations, and manufacturers to undertake an assessment of the documentation/submission/dossiers in respect of such products. As a general rule in this assessment, traditional experience means that long-term use as well as the medical, historical and ethnological background of those products shall be taken into account. Depending on the history of the country the definition of long-term use may vary but would be at least several decades. Therefore the assessment shall take into account a description in the medical/pharmaceutical literature or similar sources, or a documentation of knowledge on the application of a herbal medicine without a clearly defined time limitation. Marketing authorizations for similar products should be taken into account.

These efforts concentrate on herbal medicines, but might at a later stage be the basis for the assessment of other traditional medicines not covered by these guidelines. In the meantime, it is up to the national authorities to adapt the guidelines for assessment of traditional medicines and other herbal drugs.

Prolonged and apparently uneventful use of a substance usually offers testimony of its safety. In a few instances investigations of the potential toxicity of naturally-occurring substances widely used as ingredients in these preparations have revealed previously unsuspected potential for systematic toxicity, carcinogenicity and teratogenicity. Regulatory authorities need to be quickly and reliably informed of these findings. They should also have the authority to respond promptly to such alerts, either by withdrawing or varying the licences of registered products containing the suspect substance, or by rescheduling the substance in order to limit its use to medical prescription.

## 8.2. Assessment of quality, safety, and efficacy and intended use

### 8.2.1 Pharmaceutical assessment

This part should cover all important aspects of the quality assessment of herbal medicines. However, if a pharmacopoeia monograph exists it should be sufficient to make reference to this monograph. If no such monograph is available, a monograph must be supplied and should be set out in the same way as in an official pharmacopoeia.

All procedures should be in accordance with Good Manufacturing Practices (GMP).

#### 8.2.1.1 Crude plant material

The botanical definition, including genus, species and authority should be given to ensure correct identification of a plant. A definition and description of the part of the plant from which the medicine is made (e.g., leaf, flower, root) has to be provided as well as an indication as to whether fresh, dried or traditionally processed material is used. The active and characteristic constituents should be specified and, if possible, content limits defined. Foreign matter, impurities and microbial content should be defined or limited. Voucher specimens, representing each lot of plant material processed, should be authenticated by a qualified botanist and should be stored for at least a ten year period. A lot number should be assigned and this should appear on the product label.

#### 8.2.1.2 Plant preparations

Plant preparations include comminuted or powdered plant materials, extracts, tinctures, fatty or essential oils, expressed juices and preparations whose production involves a fractionation, purification or concentration process. The manufacturing procedure should be described in detail. If any other substance is added during the manufacture, to adjust the plant preparation to a certain level of active or characteristic constituents or for any other purpose, the added substances should be mentioned in the procedure description. A method for identification, and where possible assay of the plant preparation should be added. If the identification of an active principle is not possible, it should be sufficient to identify a characteristic substance or mixture of substances (e.g., "chromatographic fingerprint") to ensure consistent quality of the preparation.

#### 8.2.1.3 Finished product

The manufacturing procedure and formula including the amount of excipients should be described in detail. A finished product specification should be defined. A method of identification, and where possible quantification, of the plant material in the finished product should be defined. If the identification of an active principle is not possible, it should be sufficient to identify a characteristic substance or mixture of substances (e.g., "chromatographic fingerprint") to ensure consistent quality of the product. The finished product should comply with general requirements for particular dosage forms.

For imported finished products, confirmation of the regulatory status in the country of origin should be required; the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce should be applied.

#### 8.2.1.4 Stability

The physical and chemical stability of the product in the final marketing container should be tested under defined storage conditions and the shelf-life should be established.

#### 8.2.2 Safety assessment

This part should cover all relevant aspects of the safety assessment of a medicinal product. A guiding principle should be that if the product has been traditionally used without demonstrated harm no specific restrictive regulatory action should be undertaken unless new evidence demands a revised risk-benefit assessment.

A review of the relevant literature should be provided with original articles or references to the original articles. If official monograph/review results exist, reference can be made to them. However, although experience on long-term use without any evidence of risks may indicate harmlessness of a medicine, it is not certain in some cases to what extent reliance can be placed solely upon long-term usage to provide assurance of innocuity in the light of concern generated in recent years over long-term hazards of some herbal medicines.

Reported side-effects should be documented according to normal pharmacovigilance principles.

##### 8.2.2.1 Toxicological studies

If any toxicological studies are available, they should be part of the assessment. Literature should be indicated as above.

##### 8.2.2.2 Documentation of safety based on experience

As a basic rule, documentation of a long period of use should be taken into consideration when the safety is being assessed. This means that, when there are no detailed toxicological studies, documented experience on long-term use without evidence of safety problems should form the basis of the risk assessment. However, even in cases of long-used drugs, chronic toxicological risks may have occurred, but may not have been recognized. If available, the period of use, the health disorders treated, the number of users, and the countries with experience should be specified. If a toxicological risk is known, toxicity data have to be submitted. Risk assessment, whether it is independent of dose (e.g., special danger or allergies), or whether it is a function of dose, should be documented. In the second instance the dosage

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30745](https://www.yunbaogao.cn/report/index/report?reportId=5_30745)

